UNSPSC 51182040: Oxabolone

This classification denotes an anabolic steroid with the molecular formula C26H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51RPF719WE, chemically known as 4-hydroxy-19-nortestosterone but generally known as oxabolone, which bears US NIH Compound Identifier 68952. European Medicines Agency schedules Oxabolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09481MIG. The term OXABOLONE is an International Non-Proprietary Name.

World Health Organization schedules oxabolone in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, OXABOLONE remains the US FDA Preferred Term for this commodity. SMILES: CC12CCC3C(C1CCC2O)CCC4=C(C(=O)CCC34)O.

UNSPSC 51182040 Oxabolone, a Commodity code, covers anabolic steroid pharmaceutical products supplied through state and local government purchasing cooperatives and direct procurement by state agencies and health systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, which includes products classified under this code when applicable. State and local buyers source oxabolone and similar anabolic steroids through cooperative purchasing vehicles that aggregate volume across multiple jurisdictions and participating states, reducing unit costs and simplifying vendor management. Soliciting bodies include state procurement offices managing cooperative agreements that extend across state and local health facilities, hospitals, and correctional systems where such pharmaceutical agents are used under clinical protocols.

The January 2026 MMCAP RFP due March 26, 2026 represents the most recent documented activity under this code, with awarded vendors required to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with availability required by May 15, 2026 and contract effectiveness July 1, 2026. The RFP emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintenance of contracted relationships with at least two of the three authorized wholesalers. Vendors must maintain commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, with a 3 percent administrative fee assessed on all contract purchases. The contract term is two years for new responders, with optional extensions at MMCAP's sole discretion. Geographic reach extends across Minnesota and participating states including Oregon through the cooperative purchasing vehicle. No specific set-aside designations are disclosed in the available documentation.